| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
8-K: Completion of Acquisition or Disposition of Assets
- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment - |
| 05 Nov 2026 | 10-Q |
| 03 Nov 2026 |
Form 4: Carter Todd Alfred, Chief Scientific Officer
Received 33,000 shares as a grant or award · Granted 154,000 Stock Option (Right to Buy) |
| 03 Nov 2026 |
Form 4: Swartz Robin, President
Received 68,250 shares as a grant or award · Granted 318,500 Stock Option (Right to Buy) |
| 21 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Amended and Restated Employment Agreement (this “Agreement”) is made as of October 20, 2026 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Robin Swartz (the “Executive”). |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - |
| 06 Aug 2026 | 10-Q |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 13 Jul 2026 |
8-K: Other Events
On July 13, 2026, Voyager Therapeutics, Inc. (the “Company”) presented good laboratory practice (“GLP”) toxicology data for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellu... |
| 11 Jun 2026 |
Form 4: Scangos George A, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Mackey Catherine J, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Hyman Steven, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Vitale Nancy, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Higgins Michael J, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Onyia Jude, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Geraghty James A, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Colon Grace, Director
Granted 30,000 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Pierce Glenn, Director
Granted 30,000 Stock Option (Right to Buy) |
Loading...